PARTNERING TO EXPAND ACCESS

At Pfizer, we believe that all individuals deserve access to quality health care and the opportunity to lead healthy lives. We combine traditional philanthropic methods with novel approaches that create an enduring and meaningful impact on public health systems to facilitate access to health care for underserved communities around the world. This includes working in partnership with multilateral aid organizations, non-governmental organizations, government agencies and other global health stakeholders to address the complex challenges around improving health for the underserved.

“We’re working on making sure that more people than ever have access to our innovative medicines and vaccines. With an accountability mindset, where each colleague is committed to success and seizes opportunities to deliver value, we believe we will see great business results and meet the needs of our patients and society.”

JONATHAN EMMS
SENIOR VICE PRESIDENT AND HEAD, GLOBAL HEALTH & VALUE
**GAVI, THE VACCINE ALLIANCE**

Gavi, the Vaccine Alliance, through its Advanced Market Commitment, provides vaccines to the world’s poorest countries on an accelerated, affordable and sustainable basis. Pfizer has committed to supply up to 740 million doses of Prevenar 13® (pneumococcal polysaccharide conjugate vaccine, 13-valent adsorbed) through 2025. Prevenar 13 is available in more than 40 Gavi-eligible countries, with additional launches planned. We are committed to helping meet the Advanced Market Commitment’s primary goal of reducing morbidity and mortality from pneumococcal disease and, specifically, to prevent an estimated seven million childhood deaths by 2030.

### PROTECTING CHILDREN WORLDWIDE

<table>
<thead>
<tr>
<th><strong>THE NEED</strong></th>
<th><strong>PFIZER’S RESPONSE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>~14.5M CHILDREN</td>
<td>2015 marked five years of the Pfizer Gavi partnership.</td>
</tr>
<tr>
<td>ARE AFFECTED BY PNEUMOCCOCAL DISEASE EACH YEAR.</td>
<td></td>
</tr>
</tbody>
</table>

100+ COUNTRIES include Pfizer’s pneumococcal conjugate vaccine in their National Immunization Plans.

740M DOSES of Prevenar 13® pledged, through Gavi, to immunize infants and young children in the world’s poorest countries through 2025 at the lowest price available.

$3M provided by The Pfizer Foundation in 2014 for pilot programs to enhance immunization coverage in Ethiopia, Malawi, Indonesia, Pakistan, Uganda and Zambia — focused on improving the “last mile” the final step of the journey to bring vaccines to undererved infants and children.

(1) The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity from Pfizer Inc. with distinct legal restrictions.
Addressing the specific family planning needs of women in the developing world is a key priority for Pfizer. Through tremendous efforts and ongoing key collaborations, we have made great progress in bringing our injectable contraceptive, Sayana® Press (medroxyprogesterone acetate), to thousands of women living in the developing world.

In late 2014, Pfizer entered into a collaboration with the Bill & Melinda Gates Foundation and the Children’s Investment Fund Foundation to help broaden access to Sayana Press for women most in need in 69 of the world’s poorest countries. The agreement is supported by a consortium of private sector donors and aid organizations, which include PATH, the United Kingdom’s Department for International Development, the United Nations Population Fund and the U.S. Agency for International Development. Through this collaboration, Sayana Press is being sold for US$1 per dose to qualified purchasers in selected countries, which helps enable the poorest women in these countries to have access to the contraceptive at reduced or no cost.

Sayana Press combines a long-acting, reversible contraceptive with an all-in-one prefilled, single-use, non-reusable Uniject™ injection system, eliminating the need to prepare a needle and syringe. Injectable contraceptives are a widely used family planning method, particularly among women in developing countries. They are discreet, eliminate the need for a daily pill regimen and, for some women living in remote areas, they can alleviate the deterrent of having to frequently travel long distances to get to a clinic. Accordingly, experts have identified the need for a contraceptive method that can be administered in low resource, non-clinic settings.
**SAYANA PRESS AVAILABLE IN U.K. FOR ADMINISTRATION BY SELF-INJECTION**

Building on momentum towards broadening access to this contraceptive option for women across the globe, Sayana Press is the first injectable contraceptive in the United Kingdom available to women for administration by self-injection when considered appropriate by a healthcare professional. This new method of administration is also approved in additional European Union markets, including Austria, Belgium, Hungary and The Netherlands. We will continue our efforts to help bring this updated label to more countries across the globe, with an initial focus on those in the developing world — such as Burkina Faso, Senegal and Uganda — where data show unmet need and demand for injectable contraceptives. Sayana Press is not yet approved for self-injection outside of the EU.

**WIPO RE:SEARCH**

To address the gap in early stage neglected tropical disease research, the World Intellectual Property Organization (WIPO), BIO Ventures for Global Health (BVGH), and the biopharmaceutical industry came together in 2011 to develop WIPO Re:Search — a creative platform dedicated to developing new solutions, including medicines, vaccines and diagnostics, for neglected tropical diseases, as well as malaria and tuberculosis. With over 100 members from 27 countries, the consortium has facilitated over 95 partnership agreements and has arranged various research sabbaticals whereby scientists from both developed and developing countries are hosted by members of WIPO Re:Search to learn from world-class laboratories. As a founding member of WIPO Re:Search, Pfizer continues to play a leading role and is involved in several agreements where we are making specific contributions to advance external research programs targeting tuberculosis, acute diarrhea, liver stage malaria, cerebral malaria, leishmaniasis, lymphatic filariasis and fascioliasis.